🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With unshakable CONFIDENCE, finerenone and empagliflozin waltz into diabetic kidney disease - turning 'maybe someday' into 'why not today?' ✍️#NephJC summary by Sejal Lakhani, DO and Jeyakumar Meyyappan ⏰🦋Chat happening on July 8, 9 pm EST nephjc.com/news/confidenc…

Kidney disease affects 850M people and is projected to be the 5th leading cause of death by 2050, yet it’s absent from the 2025 Political Declaration of the United Nations #HLM4 on #NCDs and Mental Health draft. This must change. Read and share the open letter: theisn.org/wp-content/upl…

After decades of promising epidemiological & experimental studies, we finally realize that CKD-MBD might have been the wrong therapeutical target for dialysis patients. #HiLo (admittedly smaller than conceived, but straightforward negative). Daniel Edmonston markusathome

Underscores importance of ongoing PHOSPHATE trial evaluating liberal vs stringent PO4 control in ESKD Pop: >3,000 patients PEP: MACE Sunil Badve RathikaKrish AKTN & collaborators aktn.org.au/phosphate-tria…

Amycretin, a novel weight management medication, showed promise in two recent early-phase clinical trials. Find these trials & more in our latest issue: hubs.li/Q03wPHyW0

Well this is my bias and vote and hope. Imagine all the time and money we expend trying to lower the PO4. And pt guilt.

🚨 Finerenone Approved by US FDA in HF based on #FINEARTSHF Finerenone (Kerendia) is a non-steroidal MRA indicated to reduce the risk of CV death, hospitalization for HF, & urgent HF visits in adult patients with HF with LVEF>= 40% bayer.com/media/en-us/us…

Aldosterone synthase inhibition for primary aldosteronism

🔬 The #finerenone clinical program, FINEOVATE, includes 10+ Phase II/III trials across HF & CKD. 🔥 MOONRAKER (HF): •#FINEARTS-HF •#REDEFINE-HF •#CONFIRMATION-HF •#FINALITY-HF 🔥 THUNDERBALL (CKD): •#FIDELIO-DKD •#FIGARO-DKD •#CONFIDENCE •#FIND-CKD •#FIONA / FIONA-OLE

SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials SGLT2 inhibitors reduce the risk of hospitalizations from any cause in patients with CKD, irrespective of diabetes status, kidney function and degree of albuminuria

New Primary Aldosteronism Guidelines - simpler, streamlined, and hopefully more pragmatic. academic.oup.com/jcem/advance-a…

New episode this week! We discuss pragmatic trial infrastructure in Denmark, implementation science in nephrology and how new approaches to recruitment can improve access, equity and representation in trials #kidneycompass

Confirming what one hoped might be true, but had not been evaluated in a randomised trial - crescents modifies the efficacy of glucocorticoids in IgA nephropathy One step closer to more personalised care in IgAN Vlado Perkovic ASN Publications journals.lww.com/jasn/abstract/…

Dr. Ankeet S. Bhatt, MD, MBA offers perspective on implementation science, “the scientific study of methods and strategies that facilitate the uptake of evidence-based practice and research into regular use by practitioners and policymakers." bit.ly/3oGbHeU #TransformCVCare

In the latest episode of #KidneyCompass, Brendon Neuen , MBBS, PhD, is joined by Tor Biering-Sørensen, MD, MSc, MPH, PhD MD, MPH, PhD, and Kristoffer Grundtvig Skaarup, MD, to discuss the design, execution, and implications of the NUDGE-CKD trial. Watch now: hubs.li/Q03xMsN90

Our new data on subclinical PA and MACE is out in Circulation! For the first time, we show that renin-independant aldosterone production is associated with an increased risk of MACE independently of BP, in people mostly normotensive with low CV risk. ahajournals.org/doi/full/10.11…

Great work led by Hannah Wallace and Min Jun who spearhead our @GeorgeInstitute work using routinely collected data to better understand patterns of chronic disease care

See you there! 🌸🌸🌸